Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults

Vaccine

Volumn 14, Issue 5, 1996, Pages 446-450

  Kotloff, Karen L ^a,c   Fattom, Ali ^b   Basham, Lisa ^b   Hawwari, Abbas ^b   Harkonen, Scott ^b   Edelman, Robert ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Univax Biologics Inc   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Antibody; Group B Streptococcus; Immunization; Polysaccharide; Vaccine

Indexed keywords

POLYSACCHARIDE; STREPTOCOCCUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; NORMAL HUMAN; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 0029975046     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00147-S     Document Type: Article

References (20)

1. Schwartz, B., Schuchat, A., Oxtoby, M.J., Cochi, S.L., Hightower, A. and Broome, C.V. Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. J. Am. Med. Assoc. 1991, 266, 1112-1114
2. Centers for Disease Control and Prevention. Group B streptococcal disease in the United States, 1990: Report from a multistate active surveillance system. Morbid. Mortal. Wkly Rep. 1992, 41, 25-32
3. New Vaccine Development. Establishing Priorities. Volume I. Diseases of Importance in the United States. Institute of Medicine, National Academy Press, Washington, DC, 1985
4. Dillon, H.C., Khare, S. and Gray, B.M. Group B streptococcal carriage and disease: a 6-year prospective study. J. Ped. 1987, 110, 31-36
5. Baker, C.J. and Kasper, D.L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N. Engl. J. Med. 1976, 294, 753-756
6. Gloser, H., Bachmayer, H. and Helm, A. Intravenous immunoglobulin with high activity against group B Streptococcus. Ped. Infect. Dis. J. 5 Suppl., 1986, S176-S179
7. Baker, C.J., Edwards, M.S. and Kasper, D.L. Immunogenicity of polysaccharides from type III, group B Streptococcus. J. Clin. Invest. 1978, 61, 1107-1110
8. Eisenstein, T.K., De Cueninck, B.J., Resavy, D., Shockman, G.D., Carey, R.B. and Swenson, R.M. Quantitative determination in human sera of vaccine-induced antibody to type-specific polysaccharides of group B streptococci using an enzyme-linked immunosorbent assay. J. Infect. Dis. 1983, 147, 847-856
9. Kasper, D.L., Baker, C.J., Galdes, B., Katzenellenbogen, E. and Jennings, H.J. Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. J. Clin. Invest. 1983, 7, 260-269
10. Baker, C.J., Rench, M.A., Edwards, M.S., Carpenter, R.J., Hays, B.M. and Kasper, D.L. Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus. N. Engl. J. Med. 1988, 319, 1180-1185
11. Baker, C.J. and Kasper, D.L. Group B streptococcal vaccines. Rev. Infect. Dis. 1985, 7, 458-467
12. Levine, M.M., Black, R.E., Clements, M.L. et al. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa Strain Texas Star-SR as a live oral vaccine. Infect. Immun. 1984, 43, 515-522
13. Baker, C.J., Kasper, D.L., Tager, I.B., Paredes, A., Alpert, S., McCormack, W.M. and Goroff, D. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J. Clin. Invest. 1977, 59, 810-818
14. Basham, L.E., Pavliak, V., Li, X., Hawwari, A., Kotloff, K.L., Edelman, R. and Fattom, A. A simple, quantitative, reproducible avidin-biotin ELISA for the evaluation of group B Streptococcus type-specific antibodies in humans. Vaccine 1996, 14, 439-445
15. Mohle-Boetani, J.C., Schuchat, A., Pikaytis, D.B., Smith, J.D. and Broome, C.V. Comparison of prevention strategies for neonatal group B streptococcal infection. J. Am. Med. Assoc. 1993, 270, 1442-1448
16. Baker, C.J., Edwards, M.S. and Kasper, D.L. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics 1981, 68, 544-549
17. Stewardson-Krieger, P.B., Albrandt, K., Nevin, T., Kretschmer, R.R. and Gotoff, S.P. Perinatal immunity to group B β-hemolytic Streptococcus type Ia. J. Infect. Dis. 1977, 136, 649-654
18. Vogel, L.C., Boyer, K.M., Gadzala, C.A. and Gotoff, S.P. Prevalence of type-specific group B streptococcal antibody in pregnant women. J. Ped. 1980, 96, 1047-1051
19. Christensen, K.K., Christensen, P., Dahlander, K., Faxelius, G., Jacobson, B. and Svenningsen, N. Quantitation of serum antibodies to surface antigens of group B streptococci types Ia, Ib, and III: low antibody levels in mothers of neonatally infected infants. Scand. J. Infect. Dis. 1980, 12, 105-110
20. Paoletti, L.C., Wessels, M.R., Rodewald, A.K., Shroff, A.A., Jennings, H.J. and Kasper, D.L. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 1994, 62, 3236-3243